Ariad Pharnaceuticals Continues To Rally
Following a BMO Capital upgrade to Outperform and price target raised to $14, Ariad Pharmaceuticals (NASDAQ: ARIA) shares are 20% percent higher in Friday's trading at 9.24. Earlier in the session, the issue traded as high as 9.83. That is the highest level for ARIA since it cascaded from 17.14 on October 8, 2013.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.